Skip to content
Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

Yarrow Bioscience, Inc. (YARW)

A forensic read on Yarrow Bioscience, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution
Forensic grade
Distress
Financial health
-70.3
Distress distance
-66.3%
ROE
13.8%
Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Yarrow Bioscience, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -70.3, placing it in the Distress zone. 0 forensic signals listed from 3 of the 4 signals read.

Key fundamentals

Latest Revenue$570,000
Revenue Growth YoY+13.8%
Revenue CAGR (2yr)+15.9%
Net Margin-4646.1%
Free Cash Flow-$33.1M
Return on Equity-66.3%
Debt / Equity0.00x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Yarrow Bioscience, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.